The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio (UPCR)). This study may have two doses in two sequential cohorts. A total of 44 patients with FSGS will participate in this clinical trial and will receive the study treatment for 12 weeks.
How To Contact a Study Center:
Clinical Trial Locations